– USA, CA – QuidelOrtho Corporation (Nasdaq: QDEL), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, announced the appointments of John Chiminski and Scott Huennekens to its Board as Independent Directors, effective December 6, 2024.
As previously announced, Jim Prutow and Bob Schmidt resigned from the Board, effective November 21, 2024,
About John R. Chiminski
As a former CEO and Board Chair, John Chiminski brings a diversified medical diagnostics and pharmaceutical background, which includes operations leadership, product development and services, and a strong track record of growing global businesses. He served as CEO of Catalent (NYSE: CTLT) from 2009 to 2022, assumed the title of Chair of its board of directors in 2016, and served as Executive Chair from 2022 to 2023. He was instrumental in establishing Catalent as a standalone public company after its carve-out from Cardinal Health and transforming the company into a market leader in biopharma services.
Before that, John Chiminski spent more than 20 years with GE Healthcare in roles of increasing responsibility, ultimately serving as President and CEO of GE Medical Diagnostics, a global business with $1.9 billion in sales.
About R. Scott Huennekens
Scott Huennekens is a successful MedTech CEO, Chair, board member, entrepreneur, and investor and has been involved in over 20 startups and public companies. He served as Chair, President, and CEO of Verb Surgical, an independent surgical technology start-up jointly formed by Google and Johnson & Johnson, from 2015 to 2019. Before Verb Surgical, he was President and CEO at Volcano Corporation, a leader in minimally invasive therapy guidance in interventional cardiology, and before that, President and CEO at Digirad Corporation, a coronary imaging solutions provider.
Previously, Scott Huennekens held various leadership positions at Baxter Healthcare, Birtcher Medical Systems Deloitte, and Touche. He serves as Chair of the Board of Directors of Envista Holdings (NYSE: NVST) and as Chair of the Board of Directors of Hyperfine (Nasdaq: HYPR).
About QuidelOrtho Corporation
QuidelOrtho Corporation is a world leader in in-vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, bringing fast, accurate, and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians,s and health officials can spot trends sooner, respond quickly, er and chart the course ahead with accuracy and confidence.
Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects, and a more informed path is illuminated for each of us.
For more information: https://www.quidelortho.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.